UroGen Pharma
URGN
79 hedge funds and large institutions have $249M invested in UroGen Pharma in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 11 closing their positions.
38% more call options, than puts
Call options by funds: $4.89M | Put options by funds: $3.55M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
1.48% less ownership
Funds ownership: 67.6% → 66.12% (-1.5%)
8% less funds holding
Funds holding: 86 → 79 (-7)
47% less capital invested
Capital invested by funds: $473M → $249M (-$224M)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$13.8M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$8.28M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$7.32M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
+$4.06M |
| 5 |
HCM
Horton Capital Management
Philadelphia,
Pennsylvania
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highline Capital Management
New York
|
-$16.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.41M |
| 3 |
WCM
Wildcat Capital Management
New York
|
-$6.91M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$6.53M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.28M |
URGN Hedge Fund Activity: Q1 2020 in Review
79 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2020, worth a combined $249M — down 47% from $473M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of URGN and 4 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 30 added.
The largest buyer was Clal Insurance, adding an estimated $13.8M. The largest seller was Highline Capital Management, cutting an estimated $16.9M.
- 79 institutional investors held UroGen Pharma (URGN) as of Q1 2020, down from 86 in Q4 2019.
- Funds reported $249M of UroGen Pharma stock for Q1 2020, down 47% quarter-over-quarter.
- 4 funds opened new UroGen Pharma positions in Q1 2020 and 11 closed out, a net change of -7 holders.
- The largest UroGen Pharma buyer in Q1 2020 was Clal Insurance, an estimated $13.8M added.
- The largest UroGen Pharma seller in Q1 2020 was Highline Capital Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q1 2020.